LYEL · Lyell Immunopharma Inc. Common Stock
View on chartInsiders & Stakes
| Hans Edgar Bishop Director | ▲ Buy | Option Exercise | 4,685,614 Shares held | 9/8/2022 | View profile |
| Innovative Cellular Therapeutics Holdings Ltd | ▼ Sell | Other | 2,818,980 Shares held | 7/27/2026 | View profile |
| ARCH Venture Partners IX, LLC 10% Owner | ▲ Buy | Open Market | 1,426,528 Shares held | 3/6/2026 | View profile |
| ARCH Venture Fund XIII, L.P. 10% Owner | ▲ Buy | Open Market | 1,426,528 Shares held | 3/6/2026 | View profile |
| Klausner Richard Director | ▲ Buy | Open Market | 843,365 Shares held | 3/14/2025 | View profile |
| FRIEDMAN CATHY Director | ▼ Sell | Other | 236,370 Shares held | 12/14/2021 | View profile |
| Ramachandra Sumant | ▲ Buy | Open Market | 200,000 Shares held | 3/21/2025 | View profile |
| Matthew Lang Chief Business Officer | ▲ Buy | Grant | 162,500 Shares held | 2/10/2025 | View profile |
| Seely Lynn President and CEO | ▼ Sell | Open Market | 63,899 Shares held | 8/21/2026 | View profile |
| Otis W. Brawley Director | ▲ Buy | Open Market | 35,640 Shares held | 3/31/2025 | View profile |
| David Shook Chief Medical Officer | ▼ Sell | Open Market | 20,423 Shares held | 9/10/2026 | View profile |
| Hill Stephen J. Chief Operating Officer | ▼ Sell | Open Market | 16,816 Shares held | 8/21/2026 | View profile |
| Lee Gary K. Chief Scientific Officer | ▼ Sell | Open Market | 16,220 Shares held | 8/21/2026 | View profile |
| Charles W. Newton Chief Financial Officer | ▼ Sell | Open Market | 15,306 Shares held | 8/21/2025 | View profile |
| Bulis Veronica Sanchez VP, Corporate Controller | ▼ Sell | Open Market | 14,799 Shares held | 8/10/2026 | View profile |
Transaction History
| David Shook | ▼ Sell | Open Market | 500 | $6K | 9/10/2026 |
| Seely Lynn | ▼ Sell | Open Market | 9,589 | $149K | 8/21/2026 |
| Hill Stephen J. | ▼ Sell | Open Market | 989 | $15K | 8/21/2026 |
| Lee Gary K. | ▼ Sell | Open Market | 1,457 | $23K | 8/21/2026 |
| Bulis Veronica Sanchez | ▼ Sell | Open Market | 621 | $9K | 8/10/2026 |
| Lee Gary K. | ▼ Sell | Open Market | 131 | $2K | 8/10/2026 |
| Hill Stephen J. | ▼ Sell | Open Market | 89 | $1K | 8/10/2026 |
| Seely Lynn | ▼ Sell | Open Market | 390 | $6K | 8/10/2026 |
| Innovative Cellular Therapeutics Holdings Ltd | ▼ Sell | Other | 44,000 | $0 | 7/27/2026 |
| Innovative Cellular Therapeutics Holdings Ltd | ▼ Sell | Other | 38,500 | $0 | 7/27/2026 |
| Innovative Cellular Therapeutics Holdings Ltd | ▼ Sell | Open Market | 10 | $137 | 7/17/2026 |
| Innovative Cellular Therapeutics Holdings Ltd | ▼ Sell | Open Market | 10 | $137 | 7/16/2026 |
| Innovative Cellular Therapeutics Holdings Ltd | ▼ Sell | Other | 76,000 | $0 | 6/29/2026 |
| Innovative Cellular Therapeutics Holdings Ltd | ▼ Sell | Other | 66,500 | $0 | 6/15/2026 |
| David Shook | ▼ Sell | Open Market | 1,977 | $25K | 6/10/2026 |
| Seely Lynn | ▼ Sell | Open Market | 388 | $7K | 5/11/2026 |
| Lee Gary K. | ▼ Sell | Open Market | 130 | $2K | 5/11/2026 |
| Hill Stephen J. | ▼ Sell | Open Market | 89 | $2K | 5/11/2026 |
| Bulis Veronica Sanchez | ▼ Sell | Open Market | 217 | $4K | 5/11/2026 |
| ARCH Venture Partners IX, LLC | ▲ Buy | Open Market | 488,090 | $12.5M | 3/6/2026 |
| ARCH Venture Fund XIII, L.P. | ▲ Buy | Open Market | 488,090 | $12.5M | 3/6/2026 |
| Hill Stephen J. | ▼ Sell | Open Market | 1,236 | $29K | 2/11/2026 |
| Lee Gary K. | ▼ Sell | Open Market | 1,671 | $39K | 2/11/2026 |
| Seely Lynn | ▼ Sell | Open Market | 7,455 | $174K | 2/11/2026 |
| Hill Stephen J. | ▼ Sell | Open Market | 109 | $3K | 2/10/2026 |
| Seely Lynn | ▼ Sell | Open Market | 438 | $10K | 2/10/2026 |
| Bulis Veronica Sanchez | ▲ Buy | Grant | 8,750 | $0 | 2/10/2026 |
| Bulis Veronica Sanchez | ▼ Sell | Open Market | 254 | $6K | 2/10/2026 |
| Lee Gary K. | ▼ Sell | Open Market | 147 | $3K | 2/10/2026 |
| Hill Stephen J. | ▲ Buy | Grant | 4,000 | $0 | 2/9/2026 |
| Lee Gary K. | ▲ Buy | Grant | 4,000 | $0 | 2/9/2026 |
| Seely Lynn | ▲ Buy | Grant | 20,000 | $0 | 2/9/2026 |
| Bulis Veronica Sanchez | ▼ Sell | Open Market | 936 | $30K | 12/30/2025 |
| Bulis Veronica Sanchez | ▼ Sell | Open Market | 1,136 | $44K | 12/24/2025 |
| Seely Lynn | ▼ Sell | Open Market | 412 | $7K | 11/10/2025 |
| Bulis Veronica Sanchez | ▼ Sell | Open Market | 239 | $4K | 11/10/2025 |
| Lee Gary K. | ▼ Sell | Open Market | 138 | $2K | 11/10/2025 |
| Hill Stephen J. | ▼ Sell | Open Market | 95 | $2K | 11/10/2025 |
| Seely Lynn | ▼ Sell | Open Market | 7,257 | $77K | 8/21/2025 |
| Hill Stephen J. | ▼ Sell | Open Market | 1,004 | $11K | 8/21/2025 |
| Charles W. Newton | ▼ Sell | Open Market | 1,453 | $15K | 8/21/2025 |
| Lee Gary K. | ▼ Sell | Open Market | 1,453 | $15K | 8/21/2025 |
| Seely Lynn | ▲ Buy | Grant | 40,000 | $0 | 8/20/2025 |
| Hill Stephen J. | ▲ Buy | Grant | 8,000 | $0 | 8/20/2025 |
| Charles W. Newton | ▲ Buy | Grant | 8,000 | $0 | 8/20/2025 |
| Lee Gary K. | ▲ Buy | Grant | 8,000 | $0 | 8/20/2025 |
| Seely Lynn | ▼ Sell | Open Market | 406 | $4K | 8/12/2025 |
| Charles W. Newton | ▼ Sell | Open Market | 136 | $1K | 8/12/2025 |
| Hill Stephen J. | ▼ Sell | Open Market | 94 | $972 | 8/12/2025 |
| Lee Gary K. | ▼ Sell | Open Market | 136 | $1K | 8/12/2025 |
| Seely Lynn | ▼ Sell | Open Market | 391 | $4K | 8/11/2025 |
| Hill Stephen J. | ▼ Sell | Open Market | 91 | $958 | 8/11/2025 |
| Charles W. Newton | ▼ Sell | Open Market | 131 | $1K | 8/11/2025 |
| Lee Gary K. | ▼ Sell | Open Market | 131 | $1K | 8/11/2025 |
| David Shook | ▲ Buy | Grant | 21,900 | $0 | 6/9/2025 |
| Otis W. Brawley | ▲ Buy | Open Market | 35,640 | $20K | 3/31/2025 |
| Ramachandra Sumant | ▲ Buy | Open Market | 200,000 | $115K | 3/21/2025 |
| Charles W. Newton | ▲ Buy | Open Market | 200,000 | $112K | 3/17/2025 |
| Klausner Richard | ▲ Buy | Open Market | 158,000 | $95K | 3/14/2025 |
| Seely Lynn | ▲ Buy | Open Market | 175,000 | $106K | 3/14/2025 |
| Matthew Lang | ▲ Buy | Grant | 112,500 | $0 | 2/10/2025 |
| Seely Lynn | ▲ Buy | Grant | 337,500 | $0 | 2/10/2025 |
| Hill Stephen J. | ▲ Buy | Grant | 112,500 | $0 | 2/10/2025 |
| Charles W. Newton | ▲ Buy | Grant | 112,500 | $0 | 2/10/2025 |
| Lee Gary K. | ▲ Buy | Grant | 112,500 | $0 | 2/10/2025 |
| Matthew Lang | ▲ Buy | Grant | 50,000 | $0 | 2/9/2024 |
| Hill Stephen J. | ▲ Buy | Grant | 40,000 | $0 | 2/9/2024 |
| Lee Gary K. | ▲ Buy | Grant | 40,000 | $0 | 2/9/2024 |
| Charles W. Newton | ▲ Buy | Grant | 40,000 | $0 | 2/9/2024 |
| Seely Lynn | ▲ Buy | Grant | 200,000 | $0 | 2/9/2024 |
| Klausner Richard | ▼ Sell | Open Market | 58,020 | $132K | 8/15/2023 |
| Klausner Richard | ▼ Sell | Open Market | 11,100 | $71K | 9/23/2022 |
| Hans Edgar Bishop | ▲ Buy | Option Exercise | 145,380 | $15K | 9/8/2022 |
| Hans Edgar Bishop | ▲ Buy | Option Exercise | 993,428 | $99K | 2/23/2022 |
| FRIEDMAN CATHY | ▼ Sell | Other | 3,765,842 | $0 | 12/14/2021 |
| FRIEDMAN CATHY | ▼ Sell | Other | 218,722 | $0 | 12/14/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Lyell Immunopharma shares fall 27% over four weeks
The stock has dropped about 27% in the past month, prompting a Yahoo article that discusses factors that could support a recovery. The piece notes the recent price weakness and points to potential catalysts that may improve sentiment. The decline leaves the share price near a key support level and the RSI is low, indicating oversold conditions.
Lyell Immunopharma shares fall 27% over four weeks. The stock has dropped about 27% in the past month, prompting a Yahoo article that discusses factors that could support a recovery. The piece notes the recent price weakness and points to potential catalysts that may improve sentiment. The decline leaves the share price near a key support level and the RSI is low, indicating oversold conditions.